Given that replication stress has been associated with cancer progression, and since CHK1 inhibitors are considered in anticancer therapy, our findings may also improve an educated approach to replication checkpoint inhibition in cancer cells, by capitalizing on potential synergistic effects and reduced functionality of the recombination factors. This evidence concerns the gene CHEK1 and cancer.